Business
Alivio Awarded $3.3M from DoD to Advance ALV-304
Alivio Awarded $3.3M from DoD to Advance ALV-304.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 0197B\n PureTech Health PLC\n 05 October 2020\n \n \n \n \n 5 October 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n Alivio Therapeutics\n Awarded $3.3 Million from US Department of Defense \n \n \n \n \n Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease\n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Alivio Therapeutics, \n \n today announced \n a $3.3 million US Department of Defense (DoD) Technology/Therapeutic Development Award to advance its product candidate, ALV-304, for the treatment of inflammatory bowel disease (IBD). \n \n \n \n \n \n Alivio's inflammation-targeting, disease immunomodulation approach involves selectively restoring immune homeostasis at inflamed sites in the body, while having minimal impact on the rest of the body's immune system. \n The DoD funds will support Alivio's preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.\n \n \n \n \n \n The full text of the announcement from Alivio Therapeutics is as follows:\n \n \n \n \n Alivio Therapeutics Awarded $3.3 Million from US Department of Defense \n \n Award will support advancement of ALV-304 into the clinic for the potential treatment of inflammatory bowel disease\n \n \n BOSTON, October 5, 2020 - Alivio Therapeutics, a biotechnology company developing an inflammation-targeting disease immunomodulation platform for the potential treatment of chronic and acute inflammatory disorders, today announced a $3.3 million US Department of Defense (DoD) Technology/Therapeutic Development Award to advance its product candidate, ALV-304, for the treatment of inflammatory bowel disease (IBD). The funds will support Alivio's preclinical research and development activities to potentially enable the filing of an investigational new drug (IND) application for ALV-304.\n \n \n Alivio's inflammation-targeting, disease immunomodulation ap...